Home Featured Page 225

Featured

Latest

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics

A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report

MINDCURE Provides Update on Studies and Clinical Trials

The Missing Mushroom: Psychedelic Science and the Future of Psilocybin

COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy...

Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker...

Mydecine Files Full Patent Application Covering New Formulations that Bring Nanoemulsion...

PharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development...

Psyched Wellness Announces That the Amanita Muscaria Mushroom Has Been Successfully...

Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development...

Braxia Scientific Graduates First Cohort of Medical Professionals from Psilocybin-Assisted Therapy...

U.S. FDA Approves Nova Mentis Orphan Drug Application

EDITOR PICKS

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s;...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics

A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report

Psychedelics & Society

MINDCURE Provides Update on Studies and Clinical Trials

The Missing Mushroom: Psychedelic Science and the Future of Psilocybin

COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy...

Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker...

Mydecine Files Full Patent Application Covering New Formulations that Bring Nanoemulsion...

PharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development...

Psyched Wellness Announces That the Amanita Muscaria Mushroom Has Been Successfully...

Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development...

Braxia Scientific Graduates First Cohort of Medical Professionals from Psilocybin-Assisted Therapy...

U.S. FDA Approves Nova Mentis Orphan Drug Application

EDITOR PICKS

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s;...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY